Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ASCO 2026, the most common co-covered peer. The tracked stories average 2 original sources each. CTLA-4 appears in 1 tracked Biotech story from June 15, 2026.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ASCO 2026, the most common co-covered peer. The tracked stories average 2 original sources each. CTLA-4 appears in 1 tracked Biotech story from June 15, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CTLA-4. Shared-story counts are live from our verified record — not editorial picks.
At ASCO 2026, CStone's CS2009 trispecific antibody targeting PD-1, VEGF, and CTLA-4 revealed a differentiated safety profile and preliminary overall survival potential, positioning it as a next-gen backbone candidate that may outperform current PD-1/VEGF combos and revive CTLA-4 targeting.
Source: torontotelegraph.com · prnewswire.com
CTLA-4 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
